他汀类药物联合治疗对非肌层浸润性膀胱癌患者的潜在益处。
The potential benefits of concomitant statins treatment in patients with non-muscle-invasive bladder cancer.
发表日期：2024 Sep 10
作者：
Kang Liu, Rossella Nicoletti, Hongda Zhao, Xuan Chen, Peter Ka-Fung Chiu, Chi-Fai Ng, Renate Pichler, Laura S Mertens, Takafumi Yanagisawa, Luca Afferi, Andrea Mari, Satoshi Katayama, Juan Gomez Rivas, Riccardo Campi, Maria Carmen Mir, Michael Rink, Yair Lotan, Morgan Rouprêt, Shahrokh F Shariat, Jeremy Yuen-Chun Teoh
来源：
BJU INTERNATIONAL
摘要：
目的 研究他汀类药物对接受膀胱内卡介苗 (BCG) 辅助免疫疗法治疗的非肌层浸润性膀胱癌 (NMIBC) 患者生存结果的影响。 2001年至2020年他汀类药物处方已确定。使用 Kaplan-Meier 方法和多变量 Cox 回归分析他汀类药物组与无他汀类药物组之间的总生存期 (OS)、癌症特异性生存期 (CSS)、无复发生存期 (RFS) 和无进展生存期 (PFS)总共确定了 2602 名接受膀胱内 BCG 治疗的 NMIBC 患者。中位随访时间为 11.0 年。根据 Kaplan-Meier 分析，他汀类药物组的 OS (P<0.001)、CSS (P<0.001) 和 PFS (P<0.001) 明显更好。亚组分析表明，在 BCG 治疗之前开始他汀类药物治疗具有更好的 CSS (P = 0.02) 和 PFS (P < 0.01)。经过多变量 Cox 回归分析，“他汀类药物先于 BCG”组是 OS（风险比 [HR] 0.607，95% 置信区间 [CI] 0.514-0.716）和 CSS（HR 0.571，95% CI 0.376）的独立保护因素-0.868），但不是 RFS（HR 0.885，95% CI 0.736-1.065）和 PFS（HR 0.689，95% CI 0.469-1.013）。他汀类药物治疗似乎对接受辅助治疗的 NMIBC 患者的 OS 和 CSS 具有保护作用膀胱内卡介苗。© 2024 BJU International。
To investigate the influence of statins on the survival outcomes of patients with non-muscle-invasive bladder cancer (NMIBC) treated with adjuvant intravesical bacille Calmette-Guérin (BCG) immunotherapy.A retrospective cohort of consecutive patients with NMIBC who received intravesical BCG therapy from 2001 to 2020 and statins prescription were identified. Overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and progression-free survival (PFS) were analysed between the Statins Group vs No-Statins Group using Kaplan-Meier method and multivariable Cox regression.A total of 2602 patients with NMIBC who received intravesical BCG were identified. The median follow-up was 11.0 years. On Kaplan-Meier analysis, the Statins Group had significant better OS (P < 0.001), CSS (P < 0.001), and PFS (P < 0.001). Subgroup analysis indicated statins treatment started before BCG treatment had better CSS (P = 0.02) and PFS (P < 0.01). Upon multivariable Cox regression analysis, the 'statins before BCG' group was an independent protective factor for OS (hazard ratio [HR] 0.607, 95% confidence interval [CI] 0.514-0.716), and CSS (HR 0.571, 95% CI 0.376-0.868), but not RFS (HR 0.885, 95% CI 0.736-1.065), and PFS (HR 0.689, 95% CI 0.469-1.013).Statins treatment appears to offer protective effects on OS and CSS for patients with NMIBC receiving adjuvant intravesical BCG.© 2024 BJU International.